Rabeprazole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Rabeprazole: From Acid-Peptic Disorders to Smouldering Systemic Mastocytosis
One-Sentence Summary
Rabeprazole is a proton pump inhibitor (PPI) class drug, pharmacologically established for acid-peptic disorders (duodenal/gastric ulcer, GERD, H. pylori eradication regimens). The TxGNN model assigns a high statistical score to Smouldering Systemic Mastocytosis as a candidate new indication, but currently no clinical trials and no publications support this specific direction, and the evidence pack itself notes no known mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acid-peptic disorders (duodenal ulcer, gastric ulcer, GERD, H. pylori eradication) — PPI class; no SAHPRA-registered indication text available (drug not currently marketed in South Africa) |
| Predicted New Indication | Smouldering Systemic Mastocytosis |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not currently available for this candidate (data gap). Based on information available elsewhere in this evidence pack, Rabeprazole is a proton pump inhibitor that irreversibly inhibits gastric parietal cell H+/K+-ATPase, reducing gastric acid secretion — a mechanism well established for acid-peptic disease.
There is no known mechanistic pathway connecting proton pump inhibition to mast cell proliferation or KIT-mutation-driven disease processes, which underlie smouldering systemic mastocytosis. The evidence pack’s own repurposing rationale explicitly flags this: the high TxGNN score reflects a pure model-derived statistical signal, not a supported biological hypothesis.
Notably, other TxGNN-predicted indications for this same drug (e.g., active peptic ulcer disease, gastric ulcer disease) are supported by multiple completed Phase 2/3 RCTs and dozens of publications, reflecting mechanistically coherent extensions of the drug’s established PPI activity. By contrast, this candidate indication (rank 1 by score) has zero supporting trials or literature, illustrating that TxGNN score rank alone does not indicate evidentiary strength.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Rabeprazole currently has no SAHPRA registrations on record in this evidence pack (0 licenses, market status: not marketed). No product/dosage-form information is available to report.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: key warnings, contraindications, and drug-drug interaction data are all flagged as data gaps in this evidence pack — including a Blocking-severity gap on TFDA/SAHPRA PI warnings and contraindications — meaning safety review cannot proceed to initial screening until this data is obtained.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support, no established mechanistic link between PPI activity and mastocytosis pathophysiology, and the drug itself is not currently marketed in South Africa. The evidence level (L5, model prediction only) does not meet the threshold to advance past initial screening.
To proceed, the following is needed:
- SAHPRA/TFDA-approved Professional Information (warnings, contraindications) — currently a Blocking data gap
- Detailed mechanism-of-action (MOA) data from DrugBank
- Preclinical or mechanistic studies linking PPI/gastric acid pathways to mast cell proliferation or KIT-mutation disease
- Confirmation of any future SAHPRA registration pathway, since the drug is not currently marketed in South Africa
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.